Therapy Areas: Oncology
Targovax wins patent for Mutant-RAS neoantigen platform lead products in Europe
17 January 2019 - Immuno-oncology company Targovax ASA (OSE:TRVX) revealed on Wednesday the receipt of the European patent that will protect its mutant-RAS specific neoantigen peptides, mutant RAS spe...
Exelixis' CABOMETYX tablets receive US FDA approval
17 January 2019 - United States-based Exelixis has received approval from the United States Food and Drug Administration (FDA) for its CABOMETYX (cabozantinib) tablets intended for patients with hepat...
Biomunex Pharmaceuticals signs licensing agreement with Sanofi
17 January 2019 - France-based Biomunex Pharmaceuticals has signed a licensing agreement with France-based Sanofi.It was reported yesterday that the contract has been signed for the development of bi-...
Former Novartis CEO Named Lead Independent Director at Immunsys
16 January 2019 - - US-based clinical stage biotechnology company ImmunSYS has added Douglas G. Watson to its board of directors as lead independent director, the company said.

Watson is ...
CEL-SCI Regains Full Listing Compliance with NYSE American
16 January 2019 - - US-based cancer immunotherapies developer CEL-SCI Corp. (NYSE American: CVM)  has received notification from the staff of the NYSE American, its current listing exchange,...
Pierre Fabre and Partner Array BioPharma Reveal 15.3 Months Median OS Observed from the Phase 3 BEACON CRC Safety Lead-in of Braftovi, Mektovi and Erbitux in BRAF-Mutant Metastatic CRC
16 January 2019 - - France-based Pierre Fabre has received updated safety and efficacy results, including mature overall survival, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating th...
Related Headlines

Onstryv Approved as Parkinson's Treatment in Canada

Berman to Head R and D at Immunocore

Mirati Therapeutics doses first patient in Phase 1/2 clinical trial of MRTX849

European Commission Approves Opdivo Plus Low-Dose Yervoy for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

US Merck's Keytruda Reduced Risk of Death by 31% Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

US FDA Approves Carbometyx Tablets for Previously Treated Hepatocellular Carcinoma

Leap Therapeutics Launches Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer

CytRx Highlights Aldoxorubicin's Inclusion in New NantCell Colorectal Cancer Clinical Trial

Ascletis and Alphamab Forge Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases

Array BioPharma Sees 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination Braftovi, Mektovi and Erbitux in BRAF-Mutant Metastatic Colorectal Cancer

iReceptor Plus reports launch of international consortium project to promote human immunological data storage, integration and controlled sharing

Innovent doses first patient with IBI188 under Phase I clinical trial in China

Puma Biotechnology signs license agreement with Knight Therapeutics

Journal of Oncology Practice Publishes Manuscript from Archway Health on Reducing Costs in Oncology Care

InVivo Therapeutics Names Christopher as Chief Financial Officer